Pepducins as a potential treatment strategy for asthma and COPD.

Authors

• Reynold A Panettieri
• Tonio Pera
• Stephen B Liggett
• Jeffrey L Benovic
• Raymond B Penn

Publication/Presentation Date

6-1-2018

Abstract

Current therapies to treat asthma and other airway diseases primarily include anti-inflammatory agents and bronchodilators. Anti-inflammatory agents target trafficking and resident immunocytes and structural cells, while bronchodilators act to prevent or reverse shortening of airway smooth muscle (ASM), the pivotal tissue regulating bronchomotor tone. Advances in our understanding of the biology of G protein-coupled receptors (GPCRs) and biased agonism offers unique opportunities to modulate GPCR function that include the use of pepducins and allosteric modulators. Recent evidence suggests that small molecule inhibitors of Gα

Volume

40

First Page

120

Last Page

125

ISSN

1471-4973

Published In/Presented At

Panettieri, R. A., Pera, T., Liggett, S. B., Benovic, J. L., & Penn, R. B. (2018). Pepducins as a potential treatment strategy for asthma and COPD. Current opinion in pharmacology, 40, 120–125. https://doi.org/10.1016/j.coph.2018.04.008

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

29729548

Department(s)

Administration and Leadership

Document Type

Article